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miR-564 acts as a dual inhibitor of 
PI3K and MAPK signaling networks 
and inhibits proliferation and 
invasion in breast cancer
Merve Mutlu*, Özge Saatci*, Suhail A. Ansari, Emre Yurdusev, Huma Shehwana, Özlen Konu, 
Umar Raza & Özgür Şahin
Dysregulation of PI3K and MAPK pathways promotes uncontrolled cell proliferation, apoptotic 
inhibition and metastasis. Individual targeting of these pathways using kinase inhibitors has largely 
been insufficient due to the existence of cross-talks between these parallel cascades. MicroRNAs 
are small non-coding RNAs targeting several genes simultaneously and controlling cancer-related 
processes. To identify miRNAs repressing both PI3K and MAPK pathways in breast cancer, we re-
analyzed our previous miRNA mimic screen data with reverse phase protein array (RPPA) output, 
and identified miR-564 inhibiting both PI3K and MAPK pathways causing markedly decreased 
cell proliferation through G1 arrest. Moreover, ectopic expression of miR-564 blocks epithelial-
mesenchymal transition (EMT) and reduces migration and invasion of aggressive breast cancer cells. 
Mechanistically, miR-564 directly targets a network of genes comprising AKT2, GNA12, GYS1 and SRF, 
thereby facilitating simultaneous repression of PI3K and MAPK pathways. Notably, combinatorial 
knockdown of these target genes using a cocktail of siRNAs mimics the phenotypes exerted upon miR-564 
expression. Importantly, high miR-564 expression or low expression of target genes in combination 
is significantly correlated with better distant relapse-free survival of patients. Overall, miR-564 is a 
potential dual inhibitor of PI3K and MAPK pathways, and may be an attractive target and prognostic 
marker for breast cancer.
Breast cancer is one of the major common malignancies among women worldwide. Molecular heterogene-
ity accompanied by alterations in signaling pathways are the major factors that collectively lead to enhanced 
cellular growth, differentiation, reduced apoptosis and development of drug resistance in breast cancer1. 
Phosphatidylinositol 3-kinase (PI3K) and the mitogen activated protein kinase (MAPK) cascades are among the 
most common dysregulated signaling pathways in breast cancer. PI3K pathway is the most activated oncogenic 
pathway in 70% of tumors in patients with invasive breast cancer2. Mechanisms leading to hyperactivation of 
PI3K pathway include PIK3CA mutation (~30%), PIK3CA copy number gain, loss of PTEN protein and AKT 
activation3. AKT stimulation triggers a series of downstream effects, such as activation of transcription factors 
p53 and NF-κ B, which have major impact on cancer cell growth and survival4,5. Aberrantly activated MAPK 
pathway, on the other hand, has been observed in 2–10% of breast cancer patients3,6–8. ERK1/2 activation by phos-
phorylation is an important marker for stimulated MAPK pathway and shown to be elevated in 50% of primary 
breast tumors in comparison to adjacent normal tissue9. Activated ERK phosphorylates series of cytoplasmic and 
nuclear target proteins. ERK nuclear targets including TCF (Ternary Complex Factor) play key roles in activation 
of c-myc, c-jun and CREB transcription factors, which are important regulators of tumorigenesis10.
Over the years, several efforts have been made to inhibit cancer progression using small molecule inhibitors 
targeting specific kinases in the PI3K or MAPK pathways11,12. However, such approaches often results in limited 
success either at experimental phase or in clinical trials, mostly due to mutual cross-talk of PI3K and MAPK 
pathways interfering with the efficacies of these inhibitors11. For example, it has been shown that MAPK pathway 
is activated in the presence of RAD001, an mTOR inhibitor, by activating S6K-PI3K-Ras feedback loop13. Another 
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Figure 1. miR-564 suppresses both PI3K and MAPK pathways and reduces the viability of breast cancer cells 
via inducing a G1 cell cycle arrest. (A) Flowchart showing selection process for candidate miRNA using the data 
from miRNA mimic screen with RPPA output in MDA-MB-231 breast cancer cell line. (B) Heatmap depicting 
correlations of top 50 miRNAs with tumor suppressor or oncogenes from PI3K and MAPK pathways as well as 
cell cycle pathway from RPPA data. X-axis is classified into groups according to components involved in different 
pathways. Y-axis is clustered using hcluster from R conductor. The miRNAs above white line are potential 
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study demonstrates that ERK suppression by MEK inhibitor increases EGF-stimulated AKT activation14,15. On the 
other hand, combinatorial inhibition of both pathways often raises the high toxicity concerns16,17. In this regard, 
several studies have stipulated selecting the patients with genomic features more suitable for clinical response 
to combined inhibition of PI3K and MAPK pathways. For example, such dual-targeting strategy is shown to be 
mainly effective in patients with concurrent PI3K pathway genetic alteration and KRAS or BRAF mutation, thus 
necessitates molecular genetic profiling of patients before inhibitors treatment17–19. Our previous data also suggest 
that treatment with PI3K/mTOR inhibitor BEZ235 results in ERK upregulation, while subsequent treatment with 
lapatinib in combination with BEZ235 results in weight loss and decreased mobility of transgenic mouse models 
despite significant reduction in tumor volume20,21. These studies suggest that more research is needed to identify 
novel strategies to target these pathways simultaneously in a more effective manner.
MicroRNAs are short (18–25 nucleotides), non-coding RNAs, which bind mostly to the 3′ -untranslated region 
(3′ -UTR) of target mRNAs resulting in either mRNA cleavage or translational repression22. Human genome codes 
for more than 2600 miRNAs (miRBase Release 21), and it has been predicted that 60% of the genome is regulated 
by miRNAs23. Role of miRNAs in cancer regulation was first established 14 years ago and over the years, growing 
number of evidences have clearly indicated the involvement of dysregulated miRNAs in cancer cell proliferation, 
invasion, metastasis and drug resistance24,25. MicroRNAs can be classified either as tumor suppressor or onco-
genic depending on their tissue-specific expression patterns and the targets they regulate. In other words, miR-
NAs negatively regulating oncogenes may function as tumor suppressors while those targeting tumor suppressor 
genes serve as oncogenic miRNAs (oncomiRs)26,27. Furthermore, miRNAs tend to regulate several biological 
processes by not targeting a single gene, but combination of many genes in a network-based manner. In this 
regard, several studies including ours demonstrate the interactions between microRNAs and many genes as their 
targets in human cancer28,29. Therefore, recent work focuses on testing the potential of using miRNAs as drugs or 
drug targets. Importantly, miR-122 inhibitor (miravirsen) has been tested in Phase 2a trial in chronic hepatitis 
C patients (NCT01200420)30 while miR-34 (MRX34) has been tested in Phase 1 trial in liver cancer patients 
(NCT01829971A)31. Thus, miRNAs have a high potential as targeted therapy for cancer treatment by modulating 
several targets simultaneously.
In this study, we aimed at identifying a microRNA-based approach to target both PI3K and MAPK pathways 
simultaneously to inhibit cell proliferation and invasion in breast cancer cells. Our findings suggest that miR-564 
is a potential tumor suppressor that regulates both PI3K and MAPK signaling by directly targeting a network of 
genes (AKT2, GNA12, GYS1 and SRF) linked to these pathways, and thus controls breast cancer cells prolifer-
ation, EMT, migration and invasion. Importantly, lower levels of miR-564 expression or higher levels of target 
genes expression is associated with poor prognosis and survival suggesting miR-564 or its targets in combination 
as a potential marker for breast cancer progression.
Results
miR-564 inhibits both PI3K and MAPK pathways and reduces the viability of breast cancer cells 
via a G1 cell cycle arrest. To find a potential dual inhibitor miRNA simultaneously targeting both PI3K 
and MAPK pathways, we re-analyzed our previously published reverse phase protein array (RPPA) data28 show-
ing changes in the expression of 16 proteins involved in these two pathways and cell cycle progression upon 
transfection of MDA-MB-231 cell line with miRNA mimic library including 733 miRNAs (Fig. 1A). We clus-
tered miRNAs according to the degree (proximity) of PI3K and MAPK pathways as well as cell cycle modu-
lation upon their individual overexpression (Fig. 1B) (details are given in Methods section), and identified 23 
potential tumor suppressor miRNAs negatively co-regulating PI3K, MAPK pathways and cell cycle progression 
(Supplementary Table 1). Among these 23 miRNAs, hsa-miR-564 and hsa-miR-490 were relatively less studied in 
the context of tumor formation and progression in breast cancer. In order to test their potential tumor suppressor 
role, we performed a viability assay on breast cancer cell lines representing different clinical subtypes (TNBC, 
ER+ and HER2-overexpressed) where miR-564 and miR-490 were ectopically expressed. We observed a supe-
rior growth inhibitory effect of miR-564 over miR-490, and thus decided to focus on miR-564 for further study 
(Supplementary Fig. 1A). For further experiments, miR-564 expression levels were verified in miR-564 transiently 
transfected MDA-MB-231, MCF-7 and MDA-MB-436 cell lines as well as in MDA-MB-231 cells stably trans-
fected with miR-564 (Supplementary Fig. 1B).
To validate the RPPA data showing potential PI3K and MAPK pathway inhibition by miR-564, we exam-
ined AKT and ERK1/2 phosphorylation levels in miR-564 transfected MDA-MB-231 and MCF-7 cells, which 
represent triple negative breast cancer (TNBC) and estrogen receptor positive (ER+ ) breast cancer subtypes, 
respectively. A prominent decrease in the phosphorylation of both ERK1/2 and AKT was observed, whereas 
oncogenes while those below are potential tumor suppressors. (C) Western blots showing decreased expression 
and phosphorylation of proteins linked with PI3K and MAPK pathways. Full length western blot images for 
phospho-Akt (T308) and phospho-ERK1/2 are shown in Supplementary Fig. 6. (D) BrdU/7-AAD staining of 
MDA-MB-231 and MCF-7 cell lines transiently transfected with miR-564 or scramble control. (E) Western blot 
analyses of G1/S transition proteins in miR-564 mimic transfected MDA-MB-231 and MCF-7 cells. (F) End-point 
cell viability assay performed upon miR-564 mimic transfection in MDA-MB-231 and MCF-7 cells. (G) End-
point cell viability assay performed upon miR-564 hairpin inhibitor transfection in MCF-7 cells. (H) Real-time 
cell proliferation analysis in the presence of miR-564 transfection or control miRNA. Statistical significance of 
results was tested using paired two-tailed student t-test. (I) Expression of miR-564 in GSE40059 dataset with 12 
different breast cell lines classified as cancerous versus normal (left panel). Expression in each cell line is depicted 
as relative expression with respect to MDA-MB-468 (right panel).
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Figure 2. miR-564 inhibits migration and invasion of breast cancer cells by blocking EMT. (A) In vitro 
scratch assay with MDA-MB-231 cell line at 0 and 48 hours post-transfection with miR-564 or control miRNA. 
(B) Wound healing assay in MDA-MB-231 cell line at 0 and 48 hours post-transfection with miR-564 inhibitor 
or control hairpin inhibitor. Quantification was performed by the measurement of gap distance after cell 
migration. (C) Real-time migration assay using RTCA with MDA-MB-231 and MDA-MB-436 cells in the 
presence of miR-564 or control miRNA. (D) Real-time migration assay using RTCA with MDA-MB-231 cells 
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levels of total ERK1/2 and AKT remained unchanged upon miR-564 expression (Fig. 1C). Furthermore, we had 
observed a reduction in Cyclin D1, CDK2 and CDK4 accompanied by an increase in p27 level upon miR-564 
expression in MDA-MB-231 cell line in RPPA experiment (Fig. 1B). This instigated us to test the effect of miR-
564 on G1/S transition during cell cycle progression. We observed a G1 cell cycle arrest in MDA-MB-231 and 
MCF-7 cells transfected with miR-564 by both BrdU/7-AAD staining (Fig. 1D) as well as Western blot analysis of 
G1 and S phase associated cyclin dependent kinases (CDKs), CDK inhibitors and Retinoblastoma protein (Rb) 
phosphorylation, a key G1/S transition marker. The G1 arrest was found to be mediated by upregulation of p27 
and downregulation of CDK4 in MDA-MB-231 cells whereas it has been regulated by upregulation of p21 and 
downregulation of CDK2 in MCF-7 cells (Fig. 1E). To test if the G1 arrest induced by miR-564 overexpression 
is also reflected to growth inhibition, in addition to an end-point viability assay, we performed Real-Time Cell 
Analyzer (RTCA) assay in MDA-MB-231 and MCF-7 cells and observed a reduction in cell viability in both cell 
lines (Fig. 1F,H). Subsequently, MCF-7 cells transfected with miR-564 antagonist showed increase in cell prolif-
eration (Fig. 1G).
To further support our in vitro findings, we analyzed several publicly available cell line datasets deposited in 
Gene Expression Omnibus (GEO) database. In GSE4005932 dataset, representing mRNA and miRNA expression 
profiles of a panel of 10 different breast cancer cell lines and 2 immortalized normal breast cell lines, we found 
that miR-564 expression level was lower in breast cancer cell lines as compared to normal breast cells (Fig. 2I).
Overall, our data show that miR-564 suppresses both PI3K and MAPK pathways, and reduces the growth 
capacity of breast cancer cell lines by inducing a G1 cell cycle arrest.
miR-564 inhibits migration and invasion via blocking EMT in breast cancer cell lines. PI3K and 
MAPK pathways are known to induce epithelial-mesenchymal transition (EMT) and lead to migration and inva-
sion in different cancers33. To test if miR-564 also affects metastasis-related processes by inhibiting these path-
ways, we first examined the effect of ectopic miR-564 expression on migration of breast cancer cell lines in wound 
healing and real-time migration assays (Fig. 2A,C). For these experiments, MDA-MB-231 and MDA-MB-436 
cell lines were used as two different highly invasive breast cancer models. We observed a significant inhibition 
of migration in both MDA-MB-231 and MDA-MB-436 breast cancer cells with RTCA migration assay. In addi-
tion, migration capacity of MDA-MB-231 cells was significantly increased in the presence of miR-564 inhibitor 
transfection (Fig. 2B,D). miR-564 also significantly reduced anchorage-independent growth of MDA-MB-231 
cells stably overexpressing miR-564 as assessed by poly-HEMA assay (Fig. 2E). Furthermore, we observed a more 
epithelial-like morphology when we overexpressed miR-564 in MDA-MB-231 cells as characterized by the loss 
of stress fibers, an increase in the expression of epithelial markers (CDH1 and ZO-1) and a decrease in expres-
sion of mesenchymal markers (FN, SNAI2, ZEB1 and ZEB2) at both RNA and protein levels (Fig. 2F–H). By 
using the same dataset showing lower levels of miR-564 in breast cancer cell lines as compared to normal cell 
lines (GSE40059), we compared expression of miR-564 between less invasive and invasive cells, and observed 
significantly lower levels of miR-564 in invasive breast cell lines (Fig. 2I). Overall, in line with the known roles of 
PI3K and MAPK pathways on metastasis-related processes, miR-564 acts as a dual inhibitor of these pathways 
and leads to inhibition of anchorage-independent growth, EMT, migration and invasion in breast cancer cells.
miR-564 inhibits PI3K and MAPK pathways by targeting a network of genes in these pathways. 
Having identified miR-564 as a regulator of cell viability, migration and invasion in breast cancer, we aimed at 
identifying the targets of miR-564 mediating these observed effects. To do this, we identified miR-564 predicted 
targets by using four different publicly available miRNA target prediction databases (Targetscan (Release 6.0)34, 
miRwalk (2.0)35, DIANA36 and PITA37). Predicted targets common to two or more databases were selected for 
further analysis (Fig. 3A), and genes found in PI3K and MAPK pathways among these 37 predicted targets were 
identified by performing KEGG pathway enrichment analysis38. Five genes, namely; V-akt murine thymoma 
viral oncogene homolog 2 (AKT2), guanine nucleotide binding protein subunit alpha 12 (GNA12), glycogen 
synthase 1 (GYS1), serum response factor (SRF) and cAMP responsive element binding protein 5 (CREB5) were 
among the predicted miR-564 targets playing role in either PI3K or MAPK pathways (Supplementary Fig. 2A). 
To experimentally validate targeting of these genes by miR-564, we examined the changes in their expression in 
MDA-MB-231 and MCF-7 cells upon miR-564 overexpression. Among the five predicted target genes, four of 
them (AKT2, GNA12, GYS1 and SRF) showed decrease at mRNA (Fig. 3B) and protein levels (Fig. 3C) in both 
cell lines; therefore selected for further analysis.
As miRNAs can function by targeting several genes in a network, an approach of using a cocktail of siRNAs 
against miR-564 targets (referred here as siCocktail) would better recapitulate the effects of miR-564 overexpres-
sion by mimic transfection and could be superior against silencing only one predicted target. Therefore, we used 
upon miR-564 antagonist. (E) Poly-HEMA assay to analyze anchorage-independent growth of MDA-MB-231-luc 
cells stably-transfected with miR-564 and incubated for 48 hours. Control group was represented by cells stably-
transfected with empty vector. Tumorigenicity was quantified as percent viable cells measured with WST-1 
cell proliferation reagent. (F) DAPI/Phalloidin staining of MDA-MB-231 cell line. Images were taken 24 hours 
after transient transfection with miR-564 mimic. Cell morphology changes were quantified as ratio of long 
axis to short axis for each cell. (G) qRT-PCR showing the expression of epithelial and mesenchymal markers 
in MDA-MB-231 and MDA-MB-436 cell lines upon miR-564 mimic transfection. (H) Western blot showing 
changes in protein levels of EMT markers in miR-564 transfected MDA-MB-231 cells. (I) Expression of miR-564 
in invasive and less-invasive breast cancer cell lines from GSE40059 dataset (left panel). Expression in each cell 
line is depicted as relative expression with respect to MDA-MB-468 (right panel).
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siCocktail to knockdown all four targets of miR-564 simultaneously. We have confirmed the silencing of AKT2, 
GNA12, GYS1 and SRF by siCocktail at mRNA (Supplementary Fig. 2B) and protein levels (Supplementary Fig. 2C). 
Decreased levels of ERK1/2 and AKT phosphorylation in both MDA-MB-231 and MCF-7 cell lines upon trans-
fection with miR-564 (Fig. 1C) or siCocktail (Fig. 3D) in our Western blot analysis clearly indicated that the dual 
pathway inhibitory effects of miR-564 was, at least in part, via simultaneous targeting of AKT2, GNA12, GYS1 
and SRF.
To validate the direct targeting of AKT2, GNA12, GYS1 and SRF by miR-564 as shown at mRNA and pro-
tein levels (Fig. 3B,C), we performed dual luciferase reporter assays after cloning the 3′ -UTR of each individual 
target gene at the downstream of luciferase open reading frame (ORF). Co-transfection of 3′ -UTR vectors with 
miR-564 mimic led to a reduction in luciferase activity in both MDA-MB-231 and MCF-7 cells compared to the 
miR-Control transfected cells. Subsequently, co-transfection of miR-564 with mutated miR-564 seed-matching 
sequence containing 3′ -UTR vectors showed no significant change in luciferase activity (Fig. 3E). Conversely, 
in case of co-transfection of 3′ -UTR vectors with a hairpin inhibitor against miR-564, we observed a significant 
increase in the luciferase activity in MCF-7 cell line (Fig. 3F). In conclusion, these data demonstrate that AKT2, 
GNA12, GYS1 and SRF are the direct targets of miR-564, and miR-564 inhibits PI3K and MAPK pathways via 
targeting a network of these genes.
Combinatorial inhibition of AKT2, GNA12, GYS1 and SRF mimics the effects of miR-564 over-
expression on cell proliferation, EMT, migration and invasion. To validate that AKT2, GNA12, 
GYS1 and SRF are the major functional targets of miR-564, we examined the effects of combinatorial inhibition 
of miR-564 targets using an siCocktail on various cellular processes including viability, migration and invasion. 
Both end-point and RTCA cell viability assays showed that siCocktail mimics the growth inhibitory effects of 
Figure 3. AKT2, GNA12, GYS1 and SRF are direct targets of miR-564 and involved in dual inhibition of 
PI3K and MAPK pathway. (A) Venn diagram showing potential targets of miR-564 from 4 different target 
prediction databases. Descriptions of selected genes are given in the table below. (B) qRT-PCR results of the 
expression of potential targets upon miR-564 transfection. (C) Western blot analysis of target proteins in miR-564 
transfected MDA-MB-231 and MCF-7 cell lines. (D) Expression and phosphorylation levels of PI3K and MAPK 
pathway proteins in MDA-MB-231 and MCF-7 cells transfected with siCtrl or siCocktail. Full length western 
blot images for phospho-Akt (T308) and phospho-ERK1/2 are shown in Supplementary Fig. 6. (E) 3′ -UTR 
luciferase reporter assay in MDA-MB-231 and MCF-7 cells by dual transfection with either mimic control 
or miR-564 along with psiCHECK2 vector harboring either wild type or mutated 3′ -UTR sequence of each 
target gene. (F) 3′ -UTR luciferase reporter assay in MCF-7 cells after individual transfection with psiCHECK2 
vector DNA containing 3′ -UTR of each target gene followed by treatment with anti-miR-564 or control hairpin 
inhibitor. Relative luciferase activity was measured as the ratio of renilla/firefly luciferase.
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miR-564 in both MDA-MB-231 and MCF-7 cell lines (Fig. 4A,B). In addition, we observed that combinatorial 
inhibition of miR-564 target genes using siCocktail led to a G1 cell cycle arrest in MDA-MB-231 cells similar to 
the effect seen with miR-564 overexpression which was again mediated by upregulation of p27 and downregu-
lation of CDK4 (Fig. 4C,D). Furthermore, similar to the miR-564 overexpression, MDA-MB-231 cells have lost 
their mesenchymal morphology in the presence of siCocktail observed by DAPI/Phalloidin staining (Fig. 4E). 
Using RTCA, we showed reduced ability of MDA-MB-231 cells to migrate and invade after siCocktail treatment 
(Fig. 4F). We concluded that miR-564 inhibitory effect on migration and invasion was, at least in part, via simul-
taneous targeting of AKT2, GNA12, GYS1 and SRF. Finally, we validated the association of miR-564 targets with 
cell invasiveness using 58 cancer cell lines in NCI60 panel and 12 breast cancer cell lines from GSE40059 dataset 
where higher levels of target genes expression in combination in invasive cell lines compared to less invasive cell 
lines were observed (Fig. 4G,H). However, individual target genes’ expression did not significantly correlate with 
invasiveness in both datasets (Supplementary Fig. 3A,B). Overall, we demonstrated that miR-564 inhibits prolif-
eration, migration and invasion by targeting a network of genes found in PI3K and MAPK pathways.
miR-564 expression predicts tumor progression and better survival in breast cancer patients. 
The inhibitory effects of miR-564 on proliferation and migration of breast cancer cells led us to examine its asso-
ciation with clinic-pathological features of breast cancer patients. Importantly, analysis of GSE40525 dataset39 
showed a lower miR-564 expression in breast primary tumors as compared to matched peritumor breast tissue 
suggesting that miR-564 could have a potential inhibitory effect on tumor formation (Fig. 5A).
Figure 4. Combinatorial knockdown of AKT2, GNA12, GYS1 and SRF mimics the inhibitory effects of 
miR-564 on proliferation and migration in breast cancer cells. (A) End-point viability assay in MDA-MB-231 
and MCF-7 cell lines 48 hours post-transfection with siCtrl or siCocktail. (B) Real-time cell proliferation results 
in MDA-MB-231 and MCF-7 cell lines transfected with siCtrl or siCocktail and incubated for 48 hours. (C) Cell 
cycle analysis of MDA-MB-231 cells after transfection with siCtrl or siCocktail using BrdU/7-AAD staining. 
(D) Western blot analysis of G1/S transition proteins in MDA-MB-231 cells transiently transfected with siCtrl 
or siCocktail. (E) DAPI/Phalloidin staining of MDA-MB-231 cells. Images were taken and quantified 24 hours 
after transient transfection with siCtrl or siCocktail. Cell morphological changes were quantified as a ratio 
of long axis to short axis for each cell. (F) Real-time migration and invasion analysis of MDA-MB-231 cells 
transfected with siCtrl or siCocktail using RTCA. (G) Expression levels of target genes in combination in less-
invasive and invasive cancer cell lines from NCI60 panel. (H) Expression of target genes in combination in 
invasive and less-invasive breast cancer cell lines panel from GSE40059 dataset. Different probes of each gene 
were averaged.
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In line with our data showing decreased EMT and migration upon miR-564 overexpression (Fig. 2), we have 
observed in breast cancer patient datasets that miR-564 expression negatively correlates with tumor aggres-
siveness and metastasis. A lower miR-564 expression was present in patients with high proliferative and high 
grade tumors as compared to patients with low proliferative and low grade tumors in GEO datasets with acces-
sion numbers GSE19536, GSE22220 and GSE4026740–42 (Fig. 5B–D). Furthermore, in a dataset having miRNA 
expression in primary tumors of 14 patients and their corresponding lymph nodes and distant metastasis samples 
(GSE37407), with unpaired analysis we found significantly lower levels of miR-564 in lymph nodes and distant 
metastatic sites as compared to primary tumors (Fig. 5E), which suggests a negative correlation of miR-564 with 
breast cancer metastasis. In line with all our previous findings relating miR-564 with suppression of tumor for-
mation, progression and metastasis; in GSE38867 dataset having follow-up miRNA expression of 7 breast cancer 
patients at different stages of the disease, there was a gradual decrease in miR-564 levels as the disease progresses 
through a more aggressive stage (Fig. 5F). Strikingly, a higher miR-564 level is predictive of a significantly better 
distant relapse-free survival (DRFS) in breast cancer patients in GSE22220 dataset (Fig. 5G).
To further support the tumor suppressive roles of miR-564 in cancer, in general, we have analyzed several other 
datasets having miRNA expression of patients with different cancer types. Similar to our observations with breast 
cancer, miR-564 levels were lower in cancerous versus noncancerous tissues in a wide range of cancers including 
acute lymphoblastic leukemia (ALL), bladder cancer, osteosarcoma, prostate cancer, colon cancer and lung cancer 
(Supplementary Fig. 4A–D). In addition to this, more aggressive forms of pancreatic cancer and multiple myeloma 
were found to have lower miR-564 levels than their less aggressive counterparts (Supplementary Fig. 4E,F). These 
findings indicate that miR-564 is a potential tumor suppressor and may be utilized as a potential marker in cancer.
Figure 5. miR-564 predicts survival and suppresses tumor progression and metastasis in breast cancer 
patients. (A) miR-564 expression analysis in GSE40525 dataset containing 56 matched breast cancer patient 
samples. (B) miR-564 expression in breast cancer patients with low proliferative (LP) and high proliferative 
(HP) tumors in GSE19536 dataset. (C,D) miR-564 expression in breast cancer patients from GSE22220 and 
GSE40267 datasets grouped according to tumor grades. Data were used as it is provided. For GSE22220 dataset 
low and high grades were defined as grade 1 and 3, respectively. (E) Patient miR-564 levels in 14 primary and 27 
metastatic tumors from GSE37407 dataset. (F) miR-564 expression levels in patients showing different stages 
in breast cancer tumor progression (GSE38867). (G) Distant Relapse Free Survival (DRFS) of breast cancer 
patients from GSE22220 dataset in correlation to miR-564 expression levels. Patients were separated from 
median miR-564 expression value and survival graph had a follow-up for 5 years.
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Combined analyses of AKT2, GNA12, GYS1 and SRF expression mimic the effects of miR-564 on 
tumor progression and survival of breast cancer patients. In order to further support the functional 
roles of miR-564 target genes in PI3K and MAPK pathways and G1/S transition by using breast cancer patient 
data, we have analyzed the correlation between mRNA expression of miR-564 targets and the expression/phospho-
rylation of PI3K and MAPK pathways and cell cycle proteins by using the Cancer Genome Atlas (TCGA) data43. 
In accordance with our own RPPA data showing negative regulation of Akt1 and Akt2 by miR-564, 
we observed that there is a positive correlation between the combinatorial expression of miR-564 targets and 
phosphorylation of Akt at both Thr308 and Ser473 residues (Fig. 6A,B). We also observed a positive correlation 
between the combinatorial expression of miR-564 targets and the phosphorylated form of an mTORC1 complex 
element, PRAS40 where Thr246 phosphorylation of PRAS40 by Akt causes its dissociation from mTORC1 com-
plex leading to its activation44. Furthermore, mRNA expression of miR-564 targets was found to be negatively 
correlated with p27 protein and positively correlated with two different phosphorylated forms of p27: p27_pT157 
and p27_pT198, both of which are mediated by Akt, and prevent p27 localization in nucleus and ultimately lead 
to cell cycle progression45. These results support the notion that miR-564 targets could be important regulators of 
PI3K pathway and G1/S transition in breast cancer patients.
Finally, using GSE3494 (n = 234) and GSE22220 (n = 216) breast cancer patient microarray datasets, we ana-
lyzed the effects of combinatorial expression of target genes on patient survival. When we combined the expres-
sion of all the targets with a z-score algorithm (details are given in Methods section), we found a better survival 
of patients with low expression of miR-564 target genes than patients with high miR-564 target genes expression 
(Fig. 6E,F). In both datasets, survival curves for individual miR-564 targets were also analyzed (Supplementary 
Fig. 5A,B). Results showed that combined analysis of all target genes, rather than that of the individual genes, 
Figure 6. Expression of AKT2, GNA12, GYS1 and SRF in combination correlates with PI3K pathway 
activation in breast cancer patients and predicts survival. (A) Correlation analysis of AKT phosphorylations 
(S473 and T308) with combined mRNA expression levels of miR-564 target genes in 750 breast cancer samples 
from TCGA dataset. (B) PRAS40 phosphorylation (T246) and its correlation with mRNA levels of miR-564 
target genes in 750 breast cancer samples from TCGA dataset. (C) Protein level correlation of p27 with mRNA 
levels of target genes in 750 breast cancer patients. (D) Correlation of p27 phosphorylation levels at two 
different sites (T157 and T198) with mRNA expression levels of targets in 750 breast cancer patient samples. 
(E) Survival analysis of breast cancer patients estimated by Kaplan Meier survival curve with high (red) and low 
(blue) expression of miR-564 target genes in combination using GSE3494 (n = 234) and GSE22220 (n = 216) 
datasets.
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predicts the survival of breast cancer patients more significantly. In conclusion, combined analyses of AKT2, 
GNA12, GYS1 and SRF expression mimic the effects of miR-564 on tumor progression and survival of breast 
cancer patients.
Discussion
miR-564 has firstly been described together with six other miRNAs as potential blood-based biomarkers in schiz-
ophrenia patients46. Later report has identified downregulation of miR-564, miR-31 and miR-155 in chronic mye-
loid leukemia (CML) patients compared to non-CML patients. This study has been the first indicative of the role 
of miR-564 in cancer and also its association with MAPK, ErbB, mTOR and VEGF signaling pathways47. Recently, 
miR-564 has been recognized as a tumor suppressor miRNA in lung cancer by targeting ZIC3 protein48. However, 
the roles of miR-564 in breast cancer tumorigenesis and underlying mechanisms have not been reported yet. Our 
present study demonstrates a distinct regulatory role of miR-564 in breast cancer progression by direct targeting 
of a network of genes, namely AKT2, GNA12, GYS1 and SRF that leads to simultaneous inhibition of PI3K and 
MAPK pathways.
PI3K and MAPK pathways are among the top most commonly deregulated pathways in cancer. Effective 
interference with these pathways using appropriate inhibitors is of utmost importance in combating this disease. 
Currently, there are several available inhibitors exhibiting either selective or non-selective blockage of PI3K or 
MAPK pathways. Although satisfactory results were obtained in terms of initial response, many of these inhib-
itors were found to exhibit high toxicity, and rapid development of resistance was observed due to re-activation 
of the blocked pathway or activation of an alternative pro-survival pathway. Moreover, inhibition of either PI3K 
or MAPK pathway has been reported to trigger each other’s activity due to the presence of by-pass mechanisms 
in the form of positive or negative feedbacks as well as presence of proteins common to both pathways13,49,50. 
Several miRNAs have been demonstrated to target PI3K or MAPK pathways through different effectors and 
thus function to modulate tumor growth29,51–56. Xu et al. identified a pair of miRNAs inhibiting PI3K and MAPK 
pathways simultaneously by targeting two different closely related elements, IGF-IR and IRS1 at the upstream of 
these cascades57.
The four targets of miR-564 identified in the present study were proposed to act in concert to activate both 
PI3K and MAPK signaling pathways. Among these four miR-564 targets, AKT2, a serine-threonine kinase that 
contains SH2-like domain, is a well-known oncogene intensively studied in several cancers including breast 
cancer58,59. GNA12 is a guanine nucleotide-binding protein subunit and acts as a modulator of several signa-
ling pathways. Its function has been validated in cardiac physiology60 and maintenance of blood pressure in 
smooth muscle61. GNA12 has also been reported as a mediator of invasion by upregulating IL-6 and IL-8 in 
MDA-MB-231 breast cancer cell line62. GYS1 is a member of glycogen synthase family and mainly overexpressed 
in muscle tissues and as the name refers, it functions in glycogen metabolism. Furthermore, AKT2 can activate 
GYS1 by phosphorylating and inhibiting glycogen synthase kinase 3B (GSK-3B) which in turn phosphorylates 
and inactivates GYS163,64. SRF, serum response factor, functions as a regulator of c-fos and cell cycle progres-
sion as well as MAPK pathway downstream signaling, and it is a well-studied transcription factor in cancerous 
tissues65,66. Thus, the apparent link between these genes and proliferation or migration/invasion of cancer cells 
further supports the idea that miR-564 mediates its tumor suppressive effects, at least in part, through direct tar-
geting and functionally inhibiting these four key genes.
PI3K pathway is known to induce EMT and invasion through several effectors, like Bmi1 and EZH2 which 
downregulate PTEN and thereby activate PI3K signaling67–69. Activated PI3K signaling can, in turn, upregulate 
inducers of EMT including Snail and Slug70 as well as Rho/Rac signaling through mTOR71. Similarly, activation 
of MAPK pathway by a mutant form of BRAF has also been shown to mediate migration and invasion by upreg-
ulating a RAS effector protein RhoA and promote acquisition of EMT phenotype72. In this study, we have shown 
the blockade of EMT and decreased migration and invasion capacity of breast cancer cells upon miR-564 over-
expression, which suggests that this miRNA may also function as a metastasis suppressor by blocking these two 
pathways. Furthermore, our analysis on several cell lines and patient datasets has clearly supported the notion 
that a lower miR-564 expression may be associated with development of metastasis. Our analysis regarding the 
effect of target genes on survival of breast cancer patients revealed that similar to a better survival conferred by 
high levels of miR-564, patients expressing low levels of all four miR-564 targets exhibit a better survival in two 
different breast cancer datasets (Fig. 6A) further supporting the functional roles of these miR-564 targets in 
pathological conditions. Importantly, combinatorial expression analysis of four identified targets predict patient 
outcome better than their individual analysis. These findings further corroborate the necessity of blockade of a 
network of genes in order to obtain a desirable clinical outcome and supports potential use of miR-564 as a dual 
inhibitor of PI3K and MAPK pathways.
Collectively, our experimental results, corroborated with patient data, establish the miR-564/
AKT2-GNA12-GYS1-SRF network as a key modulator of cell proliferation, EMT migration and invasion in 
breast cancer. Here, we report a potential tumor suppressor miRNA, miR-564, functioning not only in breast 
cancer cell lines, but also in breast and other cancer patients where miR-564 level was shown to be significantly 
downregulated in tumor tissues compared to adjacent normal tissues. Furthermore, miR-564 expression is 
also associated with the invasiveness of primary breast cancer tissue and metastasis. Importantly, higher levels 
of miR-564 expression in breast cancer patients lead to better survival. Finally, our study suggests that not 
individual, but only combinatorial knockdown of AKT2, GNA12, GYS1 and SRF mimics the functions of miR-
564 as a simultaneous inhibitor of proliferation, EMT, migration and invasion of breast cancer supporting the 
notion that the mechanistic effects of miRNAs need to be examined at a network level to better elucidate their 
function.
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Methods
RPPA data analysis and candidate miRNA selection. From our previously published RPPA data 
reporting the changes in the expression of 26 proteins in the presence of 733 miRNAs in MDA-MB-231 cell 
line28, we selected 16 key proteins that are components of PI3K and MAPK pathways and cell cycle. Proteins were 
classified into two groups as potential oncogenic and tumor suppressor ones according to their roles supported 
by literature. Each miRNA was correlated with these protein classifications, and cut-off for coefficient of variation 
was 0.25. Genefilter package73 was used for correlation (cut-off |0.5|) of miRNAs, and each miRNA was assessed 
as either a tumor suppressor miRNA or an oncomiR based on its regulatory effects on known oncogenes or tumor 
suppressors in the RPPA data (Supplementary Table 1).
Cell culture. Human breast cancer cell lines (MDA-MB-231, MCF-7, BT-474 and MDA-MB-436) were 
obtained from ATCC (Manassas, VA, USA). MDA-MB-231 and MDA-MB-436 cells were cultured in Dulbecco 
Modified Eagle Medium (DMEM) (Lonza, NJ, USA) supplemented with 50 U/mL penicillin/streptomycin, 
1% non-essential amino acids and 10% fetal bovine serum (Lonza, NJ, USA). The culturing media for MCF-7 
and BT-474 cells were DMEM medium supplemented with 0.1% insulin, 50 U/mL penicillin/streptomycin, 1% 
non-essential amino acids and 10% fetal bovine serum. All cell lines were tested periodically for mycoplasma 
contamination using MycoAlert detection kit (Lonza, NJ, USA).
Transfection with miRNA mimics, expression constructs and siRNAs. Transfections with siRNAs, 
miRNA mimics or hairpin inhibitors were carried out using Lipofectamine 2000 (Invitrogen) and OptiMEM 
medium (Gibco) as previously described74. miRNA mimics, siRNAs and hairpin inhibitors (Dharmacon, 
Lafayette, CO) were used in the final concentrations of 40 nM, 40 nM and 100 nM, respectively (for sequences 
see Supplementary Table 2). A combination of individual siRNAs targeting AKT2, GNA12, GYS1 and SRF was 
used as siCocktail (final concentration was 40 nM). The 3′ -UTR vectors for AKT2, GNA12, GYS1 and SRF were 
transfected at 25 ng per well in 96-well plate format.
In vitro viability, cell cycle, migration and invasion assays. End-point cell viability assays were per-
formed by using either Cell Titer-Glo cell viability assay kit (Promega) or WST-1 reagent (Roche, Penzberg, 
Germany) as manufacturer’s protocol and were measured using Synergy HT microplate reader (BioTek, Vermont, 
USA). Real-time cell viability, migration and invasion assays were done on xCELLigence RTCA-DP (ACEA 
Biosciences Inc., CA, USA) according to manufacturer’s protocol. All RTCA measurements were normalized to 
transfection time, and statistical significance of the results was tested by paired two-tailed student t-test. Cell cycle 
analysis was performed using BrdU/7AAD flow kit (BD Biosciences, USA) as previously described28. For wound 
healing assay, 2.5 × 105 cells per well were seeded in 24-well plates, and after 48 hours of incubation following 
the transfections and scratch formation, images were taken with 5x magnification using Nikon Eclipse inverted 
microscope (Nikon, Japan). All graphics and statistical analysis were carried out in GraphPad software (GraphPad 
software Inc., La Jolla, CA, USA).
Lentiviral vector constructs and stable transfection. SMARTchoice human lentiviral hsa-miR-564 
shMIMIC hCMV-turboRFP and GIPZ non-silencing lentiviral shRNA control were purchased from Dharmacon 
(Lafayette, CO). MDA-MB-231.luc cells (a kind gift from Dr. Dihua Yu (MD Anderson, TX)) were transduced 
with miR-564 viral particles in 24-wells plate, and stably transfected cells were selected with 1 μ g/ml of puromycin 
96 hours after transduction. To produce non-silencing shRNAs control containing viral particles, HEK293FT cells 
were co-transfected with 6 μ g of GIPZ vector and 4.3 μ l of trans-lentiviral packaging mix (Dharmacon) together 
with CaCl2 reagent (Dharmacon) in 6-wells plate. 48 hours post-transfection, first viral particles were harvested. 
Stably transfected cells were selected with 1 μ g/ml of puromycin 96 hours after transduction.
PolyHEMA assay. Anchorage-independent growth of cells was measured in 96-well plates pre-coated with 
polyHEMA. The images of cells were taken at 1, 3, 5 and 7 days after transfection. All images were taken at 5X 
magnification using Nikon Eclipse inverted microscope (Nikon, Japan). To quantify the proliferation of the same 
cells, WST-1 reagent (Roche, Penzberg, Germany) was added to each well and incubated for 4 hours. Following 
incubation, absorbance was measured at 450 nm using SynergyHT microplate reader (Biotek, VT, USA).
DAPI/Phalloidin staining. Nuclear staining of MDA-MB-231 cells was done with 4,6-diamidino- 
2-phenylindole (DAPI) whereas F-actin was stained with Alexa Fluor 488 Phalloidin (1:40; Invitrogen) as previ-
ously described75. Slides were mounted (Shandon Immu-Mount, Thermo Scientific, Rockford, IL), and images 
were taken at 20x and 40x magnifications (Zeiss, Munich, Germany). Quantification of long axis/short axis ratio 
for each cell was performed as previously described75.
3′-UTR plasmid constructs, site directed mutagenesis and dual luciferase reporter assay. 
Predicted miR-564 binding sites at the 3′ -UTRs of AKT2, GNA12, GYS1 and SRF were cloned at the down-
stream of luciferase reporter gene of psiCHECK™ -2 Vector using XhoI and NotI restriction enzymes (for primer 
sequences see Supplementary Table 3). 3′ UTR plasmid constructs were mutated in every other nucleotide of 
miR-564 seed sequence (in total 4 nucleotides, for primer sequences see Supplementary Table 3). MDA-MB-231 
and MCF-7 were seeded in 96-wells plates and co-transfected with 40 nM of mimic or 100 nM hairpin inhibitors 
together with 25 ng of either 3′ -UTR vectors or mutated constructs. After transfection of 48 hours, firefly and 
renilla activities were measured with dual luciferase reporter assay system (Promega). Luminescence reading was 
taken with Synergy HT microplate reader (BioTek, Vermont, US). Renilla luminescence intensities were normal-
ized to internal firefly luminescence of psiCHECK-2 vector.
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Quantitative real-time PCR of miRNAs and mRNAs. Total RNA was isolated using TRIsure (Bioline, 
Luckenwalde, Germany) as manufacturer’s protocol. For cDNA synthesis, total RNA was reverse-transcribed 
using RevertAid RT Reverse Transcription kit (Life Technologies). Real-time PCR assay was performed using 
LightCycler® 480 SYBR Green I Master kit (Roche) (for primer sequences see Supplementary Table 3), and 
ACTB and HPRT were used as housekeeping genes. Taqman microRNA reverse transcription kit and Taqman 
gene-specific microRNA assays (Applied Biosystems, Weiterstadt, Germany) were used for miRNA quantifica-
tions according to manufacturer’s protocol. RNU44 or RNU48 were used as housekeeping genes for miRNA 
qRT-PCRs. Both mRNA and miRNA data analyzed according to Δ Δ CT method76.
Western blot analysis. Whole-cell lysates were prepared with RIPA lysis buffer containing protease inhib-
itor complete Mini (Roche, Basel), anti-phosphatase PhosSTOP (Roche, Basel), 10 mM NaF and 1 mM Na4VO3 
and quantified using BCA Protein Assay Reagent Kit (Thermo Scientific, Rockford, IL). 15 ug of total protein 
was loaded and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to PVDF 
membrane and probed with primary antibodies (Supplementary Table 4). Blots were developed using Amersham 
chemiluminescence kit (GE Health lifesciences, US).
Bioinformatics analyses of target predictions, cell line and patient datasets. For the combina-
torial target prediction analysis for miR-564, predicted targets in four different databases were downloaded. For 
TargetScan, only targets with conserved sites were selected. For DIANA and PITA, targets with a miTG score 
greater than 0.7 and a score of less than − 10 respectively were included. No cut-off was made for predicted 
targets of miRWalk. Cell line and patient data were retrieved from NCI60 cell line panel and NCBI GEO data-
bases (GSE40059, GSE40525, GSE19536, GSE22220, GSE40267, GSE37407, GSE38867, GSE31376, GSE40355, 
GSE28425, GSE14985, GSE29542, GSE37053 and GSE3494). Gene names were retrieved from specific platforms 
used in each dataset. In GSE40059, cell lines were reassigned as less invasive or invasive mostly according to their 
phenotype, invasive behavior and expression of the EMT marker genes77–80. SK-BR-3 and MDA-MB-468 cell 
lines were classified as undefined since they express low levels of E-cadherin although they are negative for two 
mesenchymal markers, Vimentin and Fibronectin, and also they have an epithelial-like or an intermediate mor-
phology77,78,80. Therefore, they were excluded from both groups and indicated as undefined. For NCI60 cell lines, 
classification of less invasive and invasive was made by Park et al.81. TCGA mRNA and RPPA data were down-
loaded from cBioPortal for Cancer Genomics82,83 and TCPA databases32, respectively. Target-network expression 
was defined as sum of z-scores of individual genes. z-score of each gene is calculated as conventional z-score 
formula using mean and population standard deviation of a gene within patients84,85. In GSE40059 dataset, log2 
expression values and the sum of z scores were normalized by subtracting the minimum value from each individ-
ual and dividing by its range. Two-tailed student t-test was used for comparisons between two patient groups with 
p = 0.05 significance cut-off. For survival graphs created by miR-564 expression, patients with less than 10 year 
distant-relapse free survival were selected 5 year cut-off was made on GSE22220 dataset. Survival graphs were 
generated by Kaplan-Meier method from Graphpad with removal of patients without any survival information or 
dead due to non-cancer cause. Patients were classified and separated from median of gene expressions. Log-rank 
test was used to calculate significance for survival plots.
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